Naturally occurring genotypic drug-resistant mutations of HBV in Huzhou, China: a single-center study
Received 25 August 2017
Accepted for publication 6 October 2017
Published 14 December 2017 Volume 2017:10 Pages 507—509
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Dr Joachim Wink
Fuchu Qian,1 Weihua Zou,2 Jiqu Qin,1 Dongli Li1
1Huzhou Key Laboratory of Molecular Medicine, 2Department of Laboratory Medicine, Huzhou Central Hospital, Huzhou, China
China is an area with highly endemic hepatitis B virus (HBV) infection, with an estimated 93 million HBV carriers, resulting in approximately 330,000 deaths annually.1 The predominant HBV genotypes in China are genotype B and C. Currently, nucleos(t)ide analogs are used for anti-HBV treatment. However, prolonged antiviral therapy may lead to drug resistance, which is associated with mutations in the reverse transcriptase region of the HBV genome. Several studies have shown that drug-resistant mutations existed in treatment-naïve patients with chronic hepatitis B (CHB). However, the prevalence rates of natural drug-resistant mutations varied in different reports.2,3 Furthermore, the prevalence and clinical profile of natural drug-resistant mutations in CHB patients are not quite clear. Thus, the purpose of this study was to investigate the prevalence and clinical feature of natural drug-resistant mutations among treatmentnaïve CHB patients in a tertiary hospital in Huzhou, eastern China.
This work was supported by grants from the Foundation Projects for Science and Technology of Huzhou City (No. 2014GY12, No. 2017GY30).
The authors report no conflicts of interest in this work.
Guo Y, Xu J, Li J, et al. An epidemiological serosurvey of hepatitis B virus shows evidence of declining prevalence due to hepatitis B vaccination in central China. Int J Infect Dis. 2015;40:75–80.
Li X, Liu Y, Zhao P, et al. Investigation into drug-resistant mutations of HBV from 845 nucleoside/nucleotide analogue-naive Chinese patients with chronic HBV infection. Antivir Ther. 2015;20:141–147.
Zhao Y, Wu J, Sun L, et al. Prevalence of mutations in HBV DNA polymerase gene associated with nucleos(t)ide resistance in treatment-naive patients with Chronic Hepatitis B in Central China. Braz J Infect Dis. 2016;20:173–178.
Qian F, Qin J, Li D, et al. Monitoring of genotypic resistance profile in chronic hepatitis B patients receiving nucleos(t)ide analogues in Huzhou, China. J Infect Dev Ctries. 2016;10:996–1002.
Zhang Q, Liao Y, Cai B, et al. Incidence of natural resistance mutations in naïve chronic hepatitis B patients: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2015;30:252–261.
Xu J, Wu B, Wang JH, et al. Pre-existing mutations in reverse transcriptase of hepatitis B virus in treatment-naive Chinese patients with chronic hepatitis B. PLoS One. 2015;10:e0117429.
Mirandola S, Sebastiani G, Rossi C, et al. Genotype-specific mutations in the polymerase gene of hepatitis B virus potentially associated with resistance to oral antiviral therapy. Antiviral Res. 2012;96:422–429.
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]